This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Astra Zeneca U.k. Limited. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: The Innovative Contributions of Yingyun Cai
Introduction
Yingyun Cai is a notable inventor based in Wilmington, DE (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies targeting the spike protein of SARS-CoV-2. His work is crucial in the ongoing fight against COVID-19.
Latest Patents
Yingyun Cai holds a patent for "Antibodies That Bind the Spike Protein of SARS-CoV-2." This patent represents a vital advancement in therapeutic options for combating the virus. With 1 patent to his name, his innovative approach showcases the importance of research in public health.
Career Highlights
Cai is currently employed at AstraZeneca U.K. Limited, where he continues to work on groundbreaking projects. His role at this leading pharmaceutical company allows him to contribute to the development of life-saving treatments. His expertise in antibody research is invaluable to the organization.
Collaborations
Yingyun Cai collaborates with talented colleagues, including Andrew Dippel and Joe Francica. Together, they work on innovative solutions that address pressing health challenges. Their teamwork exemplifies the collaborative spirit necessary for scientific advancement.
Conclusion
Yingyun Cai's contributions to biotechnology and his patent on antibodies against SARS-CoV-2 highlight his role as an influential inventor. His work at AstraZeneca U.K. Limited and collaborations with fellow researchers further emphasize the importance of innovation in addressing global health issues.